Title:
USE OF CCR5 ANTAGONISTS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER
Document Type and Number:
WIPO Patent Application WO/2016/066634
Kind Code:
A3
Abstract:
The present invention relates to CCR5 antagonists for use in the treatment of cancer, either in monotherapy or in combination therapy. The invention also relates to methods for determining whether a subject suffering from cancer benefits from an ongoing therapeutic treatment with a CCR5 antagonist or whether a subject suffering from cancer will benefit from a planned therapeutic treatment with a CCR5 antagonist.
More Like This:
Inventors:
HALAMA NIELS (DE)
JÄGER DIRK (DE)
ZOERNIG INKA (DE)
GRABE NIELS (DE)
JÄGER DIRK (DE)
ZOERNIG INKA (DE)
GRABE NIELS (DE)
Application Number:
PCT/EP2015/074850
Publication Date:
June 23, 2016
Filing Date:
October 27, 2015
Export Citation:
Assignee:
RUPRECHT KARLS UNIVERSITÄT HEIDELBERG (DE)
International Classes:
A61K39/395; A61K31/337; A61K31/46; A61K31/513; A61K31/519; A61K31/555; A61K31/7068; A61K35/00; A61K35/04
Foreign References:
| US20130303512A1 | 2013-11-14 |
Other References:
KAST R E: "Glioblastoma: Synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, vol. 35, no. 6, December 2010 (2010-12-01), BLACKWELL PUBLISHING LTD GBR, pages 657 - 663, XP002752367, ISSN: 0269-4727
ANONYMOUS: "Prepped By Tumor Cells, Lymphatic Cells Encourage Breast Cancer Cells to Spread", 3 September 2014 (2014-09-03), XP002752368, Retrieved from the Internet [retrieved on 20151217]
VELASCO-VELÁZQUEZ MARCO ET AL: "CCR5 antagonist blocks metastasis of basal breast cancer cells.", CANCER RESEARCH, vol. 72, no. 15, 1 August 2012 (2012-08-01), pages 3839 - 3850, XP002752332, ISSN: 1538-7445
ANONYMOUS: "CCR5-blockade in Metastatic Colorectal Cancer (MARACON)", 1 October 2014 (2014-10-01), XP002752333, Retrieved from the Internet [retrieved on 20141217]
CAMBIEN BÉATRICE ET AL: "CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFR[beta] in colorectal carcinoma.", PLOS ONE, vol. 6, no. 12, E28842, 2011, pages 1 - 11, XP002752334, ISSN: 1932-6203
ANONYMOUS: "Prepped By Tumor Cells, Lymphatic Cells Encourage Breast Cancer Cells to Spread", 3 September 2014 (2014-09-03), XP002752368, Retrieved from the Internet
VELASCO-VELÁZQUEZ MARCO ET AL: "CCR5 antagonist blocks metastasis of basal breast cancer cells.", CANCER RESEARCH, vol. 72, no. 15, 1 August 2012 (2012-08-01), pages 3839 - 3850, XP002752332, ISSN: 1538-7445
ANONYMOUS: "CCR5-blockade in Metastatic Colorectal Cancer (MARACON)", 1 October 2014 (2014-10-01), XP002752333, Retrieved from the Internet
CAMBIEN BÉATRICE ET AL: "CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFR[beta] in colorectal carcinoma.", PLOS ONE, vol. 6, no. 12, E28842, 2011, pages 1 - 11, XP002752334, ISSN: 1932-6203
Attorney, Agent or Firm:
BÖHMER, Thomas (Radlkoferstr. 2, München, DE)
Download PDF: